Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Aandeel

RELIEF THERAPEUTICS N CH1251125998

Laatste koers (chf)

1,260
  • Verschill

    +0,045 +3,70%
  • Volume

    25.907 Gem. (3M) 15,2K
  • Bied

    1,220  
  • Laat

    1,325  
+ Toevoegen aan watchlist

Relief therapeutics Holding

9.103 Posts
Pagina: «« 1 ... 451 452 453 454 455 456 »» | Laatste | Omlaag ↓
  1. Forecast2006 28 december 2022 16:01
    quote:

    Keeprolling schreef op 27 december 2022 18:53:

    De koers is er per saldo niets mee opgeschoten. Terug naar de beginstand vandaag.
    Komt goed, Amerika is positief op dit moment.

    Kind regards,
    Forecast
  2. forum rang 10 DeZwarteRidder 28 december 2022 16:27
    quote:

    Keeprolling schreef op 27 december 2022 18:53:

    De koers is er per saldo niets mee opgeschoten. Terug naar de beginstand vandaag.
    De koers gaat onvermijdelijk verder zakken.

    2 cent is al veel te duur.
  3. €50_is_€50 2 januari 2023 13:08
    Wat zijn hier de verwachtingen voor 2023?
    Wordt het het jaar van de ommekeer met eindelijk een product op de markt van ACER en de beursgang op Nasdaq?
  4. forum rang 10 DeZwarteRidder 2 januari 2023 13:25
    Pursuant to a Share Subscription Facility agreement (SSF),

    GEM committed to provide up to CHF 50 million to RELIEF

    THERAPEUTICS Holding SA in exchange for registered shares of

    RELIEF THERAPEUTICS Holding SA in the period from

    January 20, 2021, to January 20, 2024, at the discretion of

    RELIEF THERAPEUTICS Holding SA, subject to certain

    exceptions and limitations. No drawdowns have been made

    until December 19, 2022,resulting in a remaining balance of

    the full amount under the SSF of CHF 50 million. GEM's

    purchase position has been calculated using the closing

    price of the registered shares of RELIEF THERAPEUTICS

    Holding SA on SIX Swiss Exchange on December 19, 2022 (CHF

    0.0288) and applying the 10% discount agreed in the SSF

    (resulting in a share price of CHF 0.02592), by dividing the

    remaining balance under the SSF of CHF 50 million by such

    share price of CHF 0.02592. However, according to the

    terms of the SSF, future subscription prices under the SSF

    will correspond to 90% of the average of the closing bid

    prices on SIX Swiss Exchange during the relevant reference

    period, which corresponds to 15 trading days following

    RELIEF THERAPEUTICS Holding SA's relevant subscription

    request, subject to certain exceptions and limitations.

    Therefore, note that the actual subscription price at which

    GEM may be requested to subscribe for registered shares

    of RELIEF THERAPEUTICS Holding SA under the SSF may be lower

    or higher than the share price applied above, and

    accordingly, the number of voting rights GEM may acquire as

    a result thereof may be higher or lower than as set

    forth in this disclosure.
  5. forum rang 10 DeZwarteRidder 2 januari 2023 13:42
    quote:

    €50_is_€50 schreef op 2 januari 2023 13:34:

    Mss moeten ze aviptadil maar in China op de markt brengen, ridder! ;-p
    Dat is een heel goed idee......!!!

    Aan een zieke Chinees kun je alles verkopen wat lijkt op een geneesmiddel.........
  6. laatsteloodje 9 januari 2023 16:35
    quote:

    DeZwarteRidder schreef op 2 januari 2023 13:42:

    Aan een zieke Chinees kun je alles verkopen wat lijkt op een geneesmiddel.........
    Dat is toch heel goed nieuws. Als 0,1% van de 1,4 miljard chinesen dit nutteloos middel kopen......
  7. forum rang 10 DeZwarteRidder 5 mei 2023 11:58
    Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
    03.05.2023 / 07:00 CET/CEST

    Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares

    GENEVA (May 3, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases, today announced the implementation timeline for the reverse split of its ordinary shares, which was approved by shareholders at the Extraordinary General Meeting held on April 28, 2023.

    May 4, 2023: Last trading day of old shares on SIX Swiss Exchange
    May 5, 2023: First trading day of new shares on SIX Swiss Exchange

    As previously communicated, shareholdings will be rounded down to the next lower whole number of new merged shares by applying the 400 to 1 exchange ratio. The resulting fractions will be compensated in cash at a fixed price corresponding to the three-day volume-weighted average price of the Relief Therapeutics share on the SIX Swiss Exchange prior to the reverse split.

    Additional information on the reverse split is provided in a Q&A list available here.

    ABOUT RELIEF THERAPEUTICS

    Relief Therapeutics is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief Therapeutics’ portfolio offers a balanced mix of marketed, revenue-generating products, our proprietary, globally patented Physiomimic™ and TEHCLO™ drug delivery platform technologies and a highly targeted clinical development pipeline consisting of risk-mitigated assets focused in three core therapeutic areas: rare metabolic disorders, rare skin diseases and rare respiratory diseases. In addition, Relief Therapeutics is commercializing several legacy products via licensing and distribution partners. Our mission to provide therapeutic relief to those suffering from rare diseases is being advanced by an international team of well-established, experienced biopharma industry leaders with extensive research, development and rare disease expertise. Relief Therapeutics is headquartered in Geneva, with additional offices in Balerna, Switzerland, Offenbach am Main, Germany and Rome. Relief Therapeutics is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, please visit our website www.relieftherapeutics.com or follow Relief Therapeutics on LinkedIn and Twitter
  8. forum rang 10 DeZwarteRidder 1 september 2023 12:14
    quote:

    Ronduit schreef op 1 september 2023 12:11:

    Weer wat leven in de brouwerij. +40%, maar dat is ook niet zo gek met zo'n lage koers.
    Tjonge, jonge, zit je nog steeds met deze troep te knoeien.....????
9.103 Posts
Pagina: «« 1 ... 451 452 453 454 455 456 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in
Premium

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van BeursDuivel en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 55% korting!

Macro & Bedrijfsagenda

  1. 19 april

    1. Japan inflatie maart 2,7% YoY volitaliteit verwacht
    2. WDP Q1-cijfers
    3. EU producentenprijzen maart
    4. VK detailhandelsverkopen maart
    5. Fra ondernemersvertrouwen april
    6. KPN €0,098 ex-dividend
    7. CM.com jaarvergadering
    8. NSI jaarvergadering
    9. American Express Q1-cijfers
  2. 22 april

    1. NL investeringen februari
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht